Sumary of Astronomy meets pathology to identify predictive biomarkers for cancer immunotherapy:
- A new platform, called AstroPath, melds astronomic image analysis and mapping with pathology specimens to analyze microscopic images of tumors..
- Immunofluorescent imaging, using antibodies with fluorescent tags, enables researchers to visualize multiple cellular proteins simultaneously and determine their pattern and strength of expression..
- PD-1 (programmed cell death 1) is a protein found on immune system T cells which, when bound to another protein called PD-L1 (programmed death ligand), helps cancer cells evade attack by the immune system..
- Only some patients with melanoma respond to anti-PD-1 therapy, and the ability to predict response or resistance is critical to choosing the best treatments for each patient’s cancer, the researchers explain..
- The AstroPath platform is also being applied to study in lung cancer and potentially can provide therapeutic guidance for many other cancers..
- “For the last 40 years, pathology analysis of cancer has examined one marker at a time, which provides limited information..
- Leveraging new technology, including instrumentation to image up to 12 markers simultaneously, the AstroPath imaging algorithms provide 1,000 times the information content from a single biopsy than is currently available through routine pathology..
- This facilates precision cancer immunotherapy — identifying the unique features of each patient’s cancer to predict who will respond to a given immunotherapy, such as anti-PD-1, and who will not….